Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY.
Related news for (DBTX)
- DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. – DBTX
- Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
- Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
- Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
- Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO